Forbes  |  May 4, 2021

Intellectual property for pharmaceuticals has been a longstanding political football that has pitted the United States, where most drugs are developed, against lower income countries during international negotiations. “We can’t make highly innovative vaccine technology the purview of only the rich and the powerful,” says Lawrence Gostin, a professor of global health law at Georgetown University and director of a World Health Organization collaboration center. “We have to share it.”

Read more here.